Rapid Platform icIEF Methods Development with AESlyte HR 5–10.5 for Diverse mAbs

The AESlyte Rapid Method Development Kit is designed to make developing icIEF methods for monoclonal antibodies and other biotherapeutics quicker and easier.

Using AESlyte HR 5–10.5 with two default pI markers (5.72 & 9.71), the standardised workflow offers several benefits:

• It spans the pI range suitable for most therapeutic mAbs.
• It removes the need for ampholyte blending and simplifies method optimisation.
• It delivers robust, high-resolution, and reproducible charge variant analysis.
• It is compatible with leading commercial icIEF platforms.
• It ensures lot-to-lot consistency and a reliable supply.

The workflow was tested with 37 representative mAbs and has been successfully used for over 100 protein modalities, including mAbs, bispecific antibodies, and ADCs.

This showcases its high robustness, reproducibility, and versatile applicability from early discovery stages to quality control.

Download the technical note to discover how the AESlyte Rapid Method Development Kit can streamline and speed up your icIEF workflows.